Biomolecular Markers of Bone Metastasis
Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Jan 28, 2025
Trial Information
Current as of July 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Biomolecular Markers of Bone Metastasis," is focused on understanding how certain biological markers in the body can help predict the progression of bone metastases, which occur when cancer spreads to the bones. The researchers are specifically looking at patients who have breast, lung, renal (kidney), gastroenteric (digestive system), or prostate cancers that have spread to the bones. By studying these markers, the aim is to identify risk factors that might indicate how quickly or aggressively the bone metastasis could develop.
To be eligible for this trial, participants need to be at least 18 years old and have one of the specified types of cancer with bone metastases. Importantly, there are no specific exclusions, meaning that most patients who meet the criteria can participate. Those who join the trial will be asked to provide informed consent, letting them know what the study involves. This research is currently in the recruiting stage, and anyone interested in participating should feel free to reach out for more information.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \>= 18 years
- • Patients with breast or lung or renal or gastroenteric tract or prostate with bone metastases
- • Patients who knowingly express willingness to participate in the study after signing the written informed consent
- Exclusion Criteria:
- • None
About Irccs Azienda Ospedaliero Universitaria Di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna is a prestigious research and healthcare institution in Italy, renowned for its commitment to advancing medical science and patient care through innovative clinical research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, facilitating the translation of laboratory findings into effective treatment strategies. The institution fosters a multidisciplinary approach, collaborating with various experts to conduct high-quality clinical trials aimed at improving health outcomes across a wide range of medical fields. With a strong emphasis on ethical standards and patient welfare, IRCCS Azienda Ospedaliero-Universitaria di Bologna plays a vital role in shaping the future of medicine through rigorous scientific inquiry and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
Patients applied
Trial Officials
Andrea Sambri, MD
Principal Investigator
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported